Tag Archives: BIIB

Top Blue Chip Stocks To Buy Right Now

The major indexes rose to new highs this week as investorsignored the chaos in Washington and refused to let the market fall.

Getty Images

The S&P 500 rose 1.5% this week after advancing 0.2% to 2,351.16 today, while the Dow Jones Industrial Average gained 1.7% this week after ticking up 4.28 points to 20,624.05. The Nasdaq Composite climbed 1.8% this week after today.

There were all sorts of reasons for the market to drop this week: Fed chief Janet Yellen was more hawkish than expected when she testified to Congress this week, while President Donald J. Trump was busy defending himself, rather than proposing business friendly legislation.

But the market refused to take a loss for an answer. Today, for instance, the Dow had been down as much as 87.16 points, before rallying back, while the blue chip benchmark rallied back from a 55.03 decline. In fact, that’s been the pattern all year in the S&P 500, explains the folks at Bespoke Investment Group:

Top Blue Chip Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By Todd Campbell]

    A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.

  • [By Ben Levisohn]

    Biogen (BIIB) tumbled to the bottom of the S&P 500 today after getting cut by two analysts.

    Agence France-Presse/Getty Images

    Biogen dropped 4.7% to $278.96 at 4:19 p.m. today, while the S&P 500 declined 0.2% to 2,381.38.

    Leerinks Geoffrey Porges cited the “slower than expected ramp for Spinraza” in cutting Biogen to Market Perform from Outperform, while Morgan Stanly’s Matthew Harrison wrote that his decision to cut Biogen to Market Weight from Overweight was “not a downside call, but a timing call.”

    Biogen’s market capitalization fell to $60.2 billion today from $63.2 billion yesterday. It reported net income of $3.7 billion on sales of $10.2 billion in 2016.

    Barron’s Teresa Rivas recommended buying Biogen in December after the company released positive trial data on its Alzheimer’s drug.

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

  • [By Brian Orelli]

    While that’s fine for clinical trials, it may make it difficult for Ionis’ drugs to compete with drugs that work as well but don’t have side effects that need to be monitored. Of course, for Spinraza, which Biogen (NASDAQ:BIIB) and Ionis recently got approved for spinal muscular atrophy, side effects aren’t an issue because there aren’t any other treatment options at the moment.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Biogen Inc. (NASDAQ: BIIB) which traded down 4.6% at $279.08. The stocks 52-week range is $223.02 to $333.65. Volume was 3.4 million versus the daily average of 1.6 million shares.

Top Blue Chip Stocks To Buy Right Now: Graham Corporation(GHM)

Advisors’ Opinion:

  • [By Monica Gerson]

    Graham Corporation (NYSE: GHM) is expected to report its quarterly earnings at $0.12 per share on revenue of $23.54 million.

    Heico Corp (NYSE: HEI) is estimated to post its quarterly earnings at $0.54 per share.

Top Blue Chip Stocks To Buy Right Now: FMC Corporation(FMC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We also want to reiterate our bullish view on the agricultural commodities and the ag-related stocks (e.g., CF Industries Holdings (CF), Mosaic (MOS), Potash Corp. of Saskatchewan (POT), FMC (FMC), AGCO, Deere). Following sharp multi-year declines, trends continue to improve.

  • [By WWW.THESTREET.COM]

    With an improving global economy, now is a great time to be a chemical company, Cramer told viewers, as he reiterated his favorites: Albemarle (ALB) and FMC Technology  (FMC) .

  • [By Beth McKenna]

    Most investors interested in gaining exposure to the lithium space should stick with investing in one or more of the large players listed on a major U.S. stock exchange:Albemarle Corporation(NYSE:ALB), FMC Corp. (NYSE:FMC), andSociedad Quimica y Minera de Chile(NYSE:SQM), or SQM. Smaller players are speculative to varying degrees, and most are unprofitable.

Top Blue Chip Stocks To Buy Right Now: Aerohive Networks, Inc.(HIVE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Aerohive Networks Inc (NYSE: HIVE) were down 33 percent to $3.10. Aerohive Networks reported a Q2 loss of $3.9 million on revenue of $42.3 million, and disclosed that it has extended its $10 million buyback plan.

  • [By Monica Gerson]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.16 per share on revenue of $17.34 billion before the opening bell. Citigroup shares rose 0.47 percent to $48.70 in after-hours trading. HP Inc (NYSE: HPQ) disclosed that it would be implementing a restructuring plan that would likely result in the firing of 3,000 to 4,000 employees, annual savings of $200 million to $300 million, and a charge of $350 million to $500 million. Management also announced a 7 percent surge in the stock’s dividend and an additional $3 million share repurchase program. The company issued its outlook for fiscal 2017, guiding for EPS of $1.55 to $1.65, mostly below the Street’s consensus of $1.64. HP shares fell 1.32 percent to $14.95 in the after-hours trading session. Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.39 per share on revenue of $23.99 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.37 perecent to $67.99 in after-hours trading. Aerohive Networks Inc (NYSE: HIVE) reported weak preliminary results for its third quarter. The company said it expects a net loss of $(0.06) to $(0.07) per share, versus consensus at $(0.04) per share. Revenue guidance of $40 million also fell short of expectations for almost $48 million. Aerohive shares dropped 18.29 percent to $4.60 in the after-hours trading session.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Top 5 Tech Stocks To Invest In Right Now

Imagine your frail father dons a virtual reality headset so he can “attend” his grandson’s graduation and feel as if he’s really there. Or your mom, forgetful about her medicine, swallows a teensy sensor encased in medication that will relay the time she took the pill and the dosage to her smartphone.

SEE ALSO: Technology Helps Seniors Remain at Home

Perhaps your mother-in-law has dementia, which makes her agitated. A small robot she holds that acts like a cat, including purring, calms her instantly. Afraid shell wander? Your phone can alert you if she does.

Whether already in use or still being tested, aging-in-place technology is improving the aging experience for seniors and family caregivers. Part of the reason: the development of artificial intelligence, or AI, and “big data.” With AI, devices can react like humans after assessing a situation and learning someone’s habits. Wearable gadgetsthink Fitbit on steroidscan collect and analyze health data, while medical mini-machines monitor chronic conditions and customize treatment.

Top 5 Tech Stocks To Invest In Right Now: Attunity Ltd.(ATTU)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, ourUnder the Radar Moversnewsletter suggested small cap Big Data stock Attunity Ltd (NASDAQ: ATTU) as a short trade:

    “Attunity has also been on the watchlist for a while. It’s a straight-up momentum play Well, straight down momentum play. We’re just getting on board the train after a brief lull in the downtrend. This one isn’t going to be a monster-sized winner, but it’s a high-odds, low-risk trade.”

Top 5 Tech Stocks To Invest In Right Now: Qualstar Corporation(QBAK)

Advisors’ Opinion:

  • [By Lisa Levin]

    Qualstar Corporation (NASDAQ: QBAK) was down, falling around 16 percent to $6.99. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 million.

  • [By Jim Robertson]

    On Tuesday, our Under the Radar Moversnewsletter suggestedshorting small cap data storage systems stock Qualstar Corporation (NASDAQ: QBAK):

    Quelstar is essentially a mirror image of Pixelworks. That is, it’s not just the bearish undertow we want to tap into here. It’s the failure of QBAK to follow-through on today’s effort to break above the 100-day moving average line with today’s early effort. The market dared the bulls to play their hand, and as it turns out, they were bluffing. The sheer scope of the reversal bar in the meantime today confirms the downtrend.

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update. Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million. The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62. Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold. Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split. Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period. AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016. Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggestedpreemptively shorting small cap data storage systems stockQualstar Corporation (NASDAQ: QBAK):

Top 5 Tech Stocks To Invest In Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Biogen (BIIB)

    Biogen discovers, develops and delivers innovative therapies for the treatment of neurodegenerative diseases and autoimmune disorders.

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

  • [By WWW.THESTREET.COM]

    Breakups have the potential to create a lot of value. Just look at what Biogen (BIIB) did with its hemophilia franchise. Spun out as Bioverativ (BIVV) , shares started trading earlier this year. The stock has climbed some 23% on seemingly no news, Cramer noted.

  • [By Ben Levisohn]

    Biogen (BIIB) tumbled to the bottom of the S&P 500 today after getting cut by two analysts.

    Agence France-Presse/Getty Images

    Biogen dropped 4.7% to $278.96 at 4:19 p.m. today, while the S&P 500 declined 0.2% to 2,381.38.

    Leerinks Geoffrey Porges cited the “slower than expected ramp for Spinraza” in cutting Biogen to Market Perform from Outperform, while Morgan Stanly’s Matthew Harrison wrote that his decision to cut Biogen to Market Weight from Overweight was “not a downside call, but a timing call.”

    Biogen’s market capitalization fell to $60.2 billion today from $63.2 billion yesterday. It reported net income of $3.7 billion on sales of $10.2 billion in 2016.

    Barron’s Teresa Rivas recommended buying Biogen in December after the company released positive trial data on its Alzheimer’s drug.

  • [By Todd Campbell]

    A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Biogen Inc. (NASDAQ: BIIB) which traded down 4.6% at $279.08. The stocks 52-week range is $223.02 to $333.65. Volume was 3.4 million versus the daily average of 1.6 million shares.

Top 5 Tech Stocks To Invest In Right Now: Activision Blizzard, Inc(ATVI)

Advisors’ Opinion:

  • [By John Ballard]

    Activision Blizzard (NASDAQ:ATVI) recently reported its first-quarter results for 2017, and it was another great quarter. Over the last 12 months, players have spent about 40 billion hours playing Activision Blizzard’s games, a double-digit percentage increase over the first quarter of 2016.

  • [By Travis Hoium]

    Video game giant Activision Blizzard, Inc. (NASDAQ:ATVI) has been on a tear both on its financial statements and in the stock market over the past year. New product hits like Overwatch have combined with stalwarts like World of Warcraft and new acquisitions from King Digital to create a cash flow machine.

  • [By Demitrios Kalogeropoulos]

    If the stock market is a game, Activision Blizzard (NASDAQ:ATVI) shareholders are winning. The stock is up 60% over the past 12 months (18% in just one day last week) compared to the broader market’s 20% boost.

Top 5 Tech Stocks To Invest In Right Now: Renesola Ltd.(SOL)

Advisors’ Opinion:

  • [By Monica Gerson]

    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 9.76 percent to $1.35 in pre-market trading. ReneSola reported Q1 earnings of $0.06 per share on revenue of $260.7 million.

  • [By Monica Gerson]

    Wall Street expects ReneSola Ltd. (ADR) (NYSE: SOL) to report a quarterly loss at $0.04 per share on revenue of $256.05 million. ReneSola shares gained 2.50 percent to close at $1.23 on Friday.

  • [By Monica Gerson]

    ReneSola Ltd. (ADR) (NYSE: SOL) is estimated to report a quarterly loss at $0.04 per share on revenue of $256.05 million.

    America’s Car-Mart, Inc. (NASDAQ: CRMT) is projected to post its quarterly earnings at $0.58 per share on revenue of $149.13 million.

Best Biotech Stocks To Buy For 2018

Introduction

Corcept Therapeutics (NASDAQ:CORT) is my favorite type of biotech company. It has an approved, marketed product with ramping sales, promising pipeline candidates, and is beginning to turn a profit. Both guidance by the company and analyst coverage suggest substantial growth in earnings and revenue. While not without the inherent risks of investing in a small/mid-cap biotech companies, I believe that Corcept is an attractive, long-term investment at current levels. Before CORT announces its latest quarterly and year-end results, now is a good time to investigate this company further.

About the Company

Corcept was founded in 1998 and has focused on the effects of an overabundance of cortisol as well as the potential benefits of developing glucocorticoid receptor antagonists (GRAs). Approximately 80 percent of the body’s tissues have receptors for cortisol. Excess cortisol can be life-threatening if not treated effectively. In February of 201 2, the FDA approved Korlym (mifepristone) for a once-daily oral dose to treat hyperglycemia secondary to hypercortisolism, excess cortisol, in adult patients with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or surgery has failed.

Best Biotech Stocks To Buy For 2018: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in i ts favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

Best Biotech Stocks To Buy For 2018: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By Brian Orelli]

    While that’s fine for clinical trials, it may make it difficult for Ionis’ drugs to compete with drugs that work as well but don’t have side effects that need to be monitored. Of course, for Spinraza, which Biogen (NASDAQ:BIIB) and Ionis recently got approved for spinal muscular atrophy, side effects aren’t an issue because there aren’t any other treatment options at the moment.

  • [By WWW.MONEYSHOW.COM]

    Biogen (BIIB)

    Biogen discovers, develops and delivers innovative therapies for the treatment of neurodegenerative diseases and autoimmune disorders.

Best Biotech Stocks To Buy For 2018: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    RBC’s Simos Simeonidis and Matthew Eckler try to find the right comparison for Pfizer’s (PFE) purchase of Medivation (MDVN):

    Scott Eisen/Bloomberg News

    We were obviously wrong with our Sector Perform rating: while we knew an M&A transaction was definitely a good possibility, we just could not get to this level of valuation using a realistic Xtandi model and thus could not recommend the stock. The only way for us to get to $81.50 (or even to $60-$70/share) would have been to assign very significant value to talazoparib. And we could not do that given the amount of available clinical evidence.Medivation shareholders who held on to their shares past the $50′s, did just that, were proven right and are now rewarded for it, since they believed that someone would be willing to pay for this asset just months ahead of Phase III data. The key question is why would a company be willing to part with what they claim/think may be a multibillion dollar drug that works in multiple cancers. We believe the obvious answer is because they’re smart and understand drug development risk better than most. We’ll know in a matter of months whether Pfizer/Medivation is like Amgen (AMGN)-Onyx (carfilzomib) or not.

  • [By Ben Levisohn]

    Medivation (MDVN) has soared 20% to $80.41 after agreeing to be purchased for $14 billion, or $81.50 a share, by Pfizer (PFE). Pfizer has declined 0.7% to $34.75.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

    PACCAR Inc (NASDAQ: PCAR) Aug16 52.5 Puts: 10000 @ ASK $1.70: 10k traded vs 335 OI: Earnings 7/26 $54.94 Ref Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Jul16 345 Puts: 949 @ ASK $8.70: 1003 traded vs 55 OI: Earnings 8/2 $360.20 Ref NVIDIA Corporation (NASDAQ: NVDA) Fri 6/24 47.0 Puts (Wkly) Sweep: 689 @ ASK $1.12: 3758 traded vs 136 OI: Earnings 8/4 $46.69 Ref Medivation Inc (NASDAQ: MDVN) Sep16 55.0 Puts: 4000 @ Above Ask! $3.40: 5303 traded vs 716 OI: Earnings 8/4 $59.44 Ref Expeditors International of Washington (NASDAQ: EXPD) Aug16 47.0 Puts Sweep: 950 @ ASK $1.35: 973 traded vs 381 OI: Earnings 8/2 $48.15 Ref

    Posted-In: Huge Put PurchasesNews Options Markets

  • [By Ben Levisohn]

    Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance, the delta in the average PEG ratio for biotech growth companies (excluding Medivation (MDVN)) compared to non-biotech growth companies is slightly wider than it’s been for most of the year. As such, we remain constructive on the sector. That said, while valuations are attractive on a relative basis, there remains some uncertainty for the group and we would not be surprised to see the volatility continue…

  • [By Ben Levisohn]

    Well, it looks like Medivation (MDVN) now has five suitors after reports that Amgen (AMGN) is joining Pfizer (PFE), Sanofi (SNY), AstraZeneca (AZN) and Novartis (NVS) in considering a bid. Maxim’s Jason Kolbert and Jason McCarthy offer their thoughts:

    Medivation reports tonight at 4:30pm…

    We expect the focus to be on the recent proposals from Sanofi (SNY $38.75- NR); Pfizer (PFE $33.40 -NR), AstraZeneca (AZN $28.26-NR) and just today, Amgen (AMGN – $154.18 – NR)…

    Medivation is returning to new highs as suitors line up to make acquisition bids. In this scenario what is the right discount rate for modeling purposes?

    We believe our model for Xtandi revenues is good, therefore we review our risk rating and determine the following: 30% = $47 15% = $76 10% = $99

    With Medivation’s board having now said No to anything less than $65 per share, it suggests to us that the stability and predictability of Xtandi’s revenues is greater than we thought, the risk is lower. Our intermediate risk rating is 15% or $76 fair value.

    Shares of Medivation rose 0.3% to $59.22 today, while Pfizer gained 0.5% to $33.56, Sanofi fell 0.5% to $39.07, AstraZeneca dropped 0.6% to $39.07, Novartis declined 0.3% to $74.12, and Amgen ticked up 0.1% to $154.25.

     

Best Biotech Stocks To Buy For 2018: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.